Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634508 | 0.89 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1L3MBTL1EGFR | |
| SCHEMBL634901 | 0.82 | ALDH1A1 (0.63) | ALDH1A1KMT2AMEN1L3MBTL1EGFR | |
| SCHEMBL19086823 | 0.79 | TAAR1 (0.47) | ALDH1A1KMT2AMEN1L3MBTL1EGFR | |
| SCHEMBL15177631 | 0.78 | EGFR (0.46) | ALDH1A1KMT2AMEN1L3MBTL1EGFR | |
| SCHEMBL3440085 | 0.78 | ALDH1A1 (0.57) | ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3440027 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1L3MBTL1EGFR | |
| SCHEMBL3440029 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1L3MBTL1EGFR | |
| SCHEMBL2115291 | 0.75 | EGFR (0.43) | ALDH1A1KMT2AMEN1L3MBTL1EGFR | |
| SCHEMBL3440025 | 0.75 | ALDH1A1 (0.77) | ALDH1A1KMT2AMEN1L3MBTL1NPC1 | |
| SCHEMBL3440030 | 0.74 | ALDH1A1 (1.00) | ALDH1A1KMT2AMEN1L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-8524750-B2 | (Pyrazol-3-yl)-1,3,4-thiadiazol-2-amine and (pyrazol-3-yl)-1,3,4-thiazol-2-amine compounds | GLAXO GROUP LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| EP-2419426-B1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2013-08-14 | — | — | EP | disclosed |
| EP-2419426-B1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| EP-2419426-A1 | ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS | Glaxo Group Limited (GB) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010118852-A1 | ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118852-A1 | ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095064-A1 | (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS | H1-3, CHRM2, TBL3 | ALDH1A1 2718/4885KMT2A 2219/4885MEN1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.